Capricor Therapeutics Relocates HQ to San Diego
Ticker: CAPR · Form: 8-K · Filed: Jan 11, 2024 · CIK: 1133869
| Field | Detail |
|---|---|
| Company | Capricor Therapeutics, Inc. (CAPR) |
| Form Type | 8-K |
| Filed Date | Jan 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $10.0 million |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance
TL;DR
**Capricor Therapeutics just moved its main office, nothing major for the stock.**
AI Summary
Capricor Therapeutics, Inc. filed an 8-K on January 11, 2024, to update its principal executive offices from Beverly Hills, CA to 10865 Road to the Cure, Suite 150, San Diego, California 92121. This change is a routine administrative update and does not indicate any significant operational or financial shifts. For investors, this simply means the company's physical headquarters has moved, which is generally not a material event affecting stock value unless it signals broader strategic changes not disclosed here.
Why It Matters
This filing is a routine administrative update about Capricor Therapeutics' change of address, which typically has no direct impact on the company's financial performance or stock price.
Risk Assessment
Risk Level: low — This filing is purely administrative, reporting a change of address, and carries no inherent financial or operational risk.
Analyst Insight
Smart investors would note this administrative update but understand it has no immediate bearing on the company's fundamentals or investment thesis, requiring no specific action.
Key Players & Entities
- CAPRICOR THERAPEUTICS, INC. (company) — the registrant filing the 8-K
- January 11, 2024 (date) — date of earliest event reported
- 8840 WILSHIRE BLVD, 2ND FLOOR, BEVERLY HILLS, CA 90211 (address) — former business address
- 10865 Road to the Cure, Suite 150, San Diego, California 92121 (address) — new principal executive offices
FAQ
What is the primary purpose of this 8-K filing by Capricor Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report a change in the principal executive offices of Capricor Therapeutics, Inc., as indicated by the updated address from Beverly Hills to San Diego.
What was Capricor Therapeutics, Inc.'s previous principal executive office address?
Capricor Therapeutics, Inc.'s previous principal executive office address was 8840 WILSHIRE BLVD, 2ND FLOOR, BEVERLY HILLS, CA 90211.
What is Capricor Therapeutics, Inc.'s new principal executive office address?
Capricor Therapeutics, Inc.'s new principal executive office address is 10865 Road to the Cure, Suite 150, San Diego, California 92121.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 11, 2024.
Does this 8-K filing indicate any change in Capricor Therapeutics, Inc.'s state of incorporation or IRS Employer Identification Number?
No, this 8-K filing does not indicate any change in Capricor Therapeutics, Inc.'s state of incorporation (Delaware) or IRS Employer Identification Number (88-0363465). It only reports a change in the physical address of its principal executive offices.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-01-11 09:00:12
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M
- $10.0 million — received its first milestone payment of $10.0 million from Nippon Shinyaku, Co., Ltd. under i
Filing Documents
- capr-20240111x8k.htm (8-K) — 33KB
- 0001558370-24-000197.txt ( ) — 146KB
- capr-20240111.xsd (EX-101.SCH) — 3KB
- capr-20240111_lab.xml (EX-101.LAB) — 15KB
- capr-20240111_pre.xml (EX-101.PRE) — 9KB
- capr-20240111x8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. On January 11, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the "Company"), announced that it has received its first milestone payment of $10.0 million from Nippon Shinyaku, Co., Ltd. under its U.S. Exclusive Commercialization and Distribution Agreement dated January 24, 2022. The milestone payment was triggered by the receipt of results of the interim futility analysis, reviewed by the Data Safety Monitoring Board, resulting in a favorable recommendation to continue the HOPE-3 trial as planned. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: January 11, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3